SCHEMBL9945313

SCHEMBL9945313

C=CC[S+]([O-])C/C=C/SC(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9945299 0.78
SCHEMBL10729299 0.74
SCHEMBL10729290 0.74
SCHEMBL9945298 0.74
SCHEMBL10723552 0.72 PTGS2 (0.30)
SCHEMBL10723564 0.72 PTGS2 (0.30)
SCHEMBL9635 0.71
(Z)-Ajoene SCHEMBL3305767 0.69 PTGS2 (0.46)
Ajoene SCHEMBL3341704 0.69 PTGS2 (0.46)
Ajoene SCHEMBL465526 0.69 PTGS2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149940-A1 Integrin Modulators and Methods for Their Use BILLINGS PHARMACEUTICALS, INC. 2012-06-14 US disclosed
US-20100099917-A1 Integrin modulators and methods for their use BILLINGS PHARMACEUTICALS, INC. 2010-04-22 US disclosed
US-20080234388-A1 Integrin Modulators and Methods for their Use BILLINGS PHARMACEUTICALS, INC. 2008-09-25 US disclosed
US-20080234388-A1 Integrin Modulators and Methods for their Use BILLINGS PHARMACEUTICALS, INC. 2008-09-25 US disclosed